Alpha 1 antitrypsin modified process - Grifols
Alternative Names: Alpha-1 MP - Grifols; Alpha-1 proteinase-inhibitor-modified process - Grifols; Alpha-1-antitrypsin IV - Grifols; Alpha-1-protease-inhibitor-modified process - Grifols; Alpha-antitrypsin modified process - Grifols; Alpha1-PI; Lynspad; Prolastin; Prolastin-C; Prolastin-C Liquid; Prolastina; Pulmolast; TAL 6004Latest Information Update: 05 Nov 2023
At a glance
- Originator Bayer
- Developer CSL Vifor; Grifols
- Class Acute-phase proteins; Alpha globulins; Anti-inflammatories; Antiallergics; Antihyperglycaemics; Blood proteins; Secretory proteinase inhibitory proteins; Serpins
- Mechanism of Action Immunomodulators; Serine endopeptidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Alpha 1-antitrypsin deficiency
- Phase II Chronic fatigue syndrome; COVID 2019 infections; Type 1 diabetes mellitus
Most Recent Events
- 13 Jul 2023 Grifols completes enrolment in its phase III trial for Alpha 1-antitrypsin deficiency in USA, Canada, Australia, Germany, Brazil, New Zealand, Ireland, Denmark, Estonia, Finland, France, Poland, Russia, Romania, Sweden, Spain (NCT01983241)
- 29 Sep 2022 CTP push 270267 - KDM added
- 02 Aug 2022 Vifor Pharma has been acquired by CSL and renamed to CSL Vifor